Review discusses thymoquinone's potential in improving cognitive performance in Alzheimer's models, indicating a need for further clinical studies.
accumulation, modulate tau-related pathology, and improve neuronal survival and cognitive performance in several AD models. The review also discusses delivery strategies to improve the bioavailability and brain targeting of TQ, including nanoformulation-based approaches. Although the available pre-clinical findings support the therapeutic promise of TQ. The well-designed clinical studies are required to establish its efficacy, safety, optimal dosing, and long-term translational value in treating AD.
No takes yet. Share an insight, caveat, or question.
Kaur et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: